MARKET

XNCR

XNCR

Xencor
NASDAQ

Real-time Quotes | Nasdaq Last Sale

28.46
-1.83
-6.04%
After Hours: 28.46 0 0.00% 16:56 03/27 EDT
OPEN
29.41
PREV CLOSE
30.29
HIGH
30.37
LOW
27.75
VOLUME
317.02K
TURNOVER
--
52 WEEK HIGH
46.33
52 WEEK LOW
19.35
MARKET CAP
1.62B
P/E (TTM)
64.51
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of XNCR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average XNCR stock price target is 44.25 with a high estimate of 56.00 and a low estimate of 21.00.

EPS

XNCR News

More
  • The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Xencor Licenses Tech To Vir For COVID-19 Treatment, Delay In Pfizer's Upjohn-Mylan Merger
  • Benzinga · 3d ago
  • Vir inks deal with Xencor for antibody-extending technology
  • seekingalpha · 4d ago
  • Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend XmAb® Antibody Technology in Investigational Antibodies to Treat COVID-19
  • Business Wire · 4d ago
  • Benzinga's Top Upgrades, Downgrades For March 4, 2020
  • Benzinga · 03/04 15:08

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About XNCR

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.
More

Webull offers kinds of Xencor Inc stock information, including NASDAQ:XNCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XNCR stock news, and many more online research tools to help you make informed decisions.